• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Mainz Biomed N.V.

    5/22/26 12:32:00 PM ET
    $QUCY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $QUCY alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001561662
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Quantum Cyber N.V.
    SEC File Number
    001-41010
    Address of Issuer
    ROBERT KOCH STRASSE 50
    MAINZ
    GERMANY
    55129
    Phone
    49 6131 5542860
    Name of Person for Whose Account the Securities are To Be Sold
    BAECHLER GUIDO
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Fidelity Brokerage Services LLC
    245 Summer Street
    Boston � MA � 02110
    240000904800.001466116905/22/2026
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common04/22/2026Stock AwardIssuerCheckbox not checked24000004/22/2026Compensation

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    Guido Baechler
    1501 Belvedere Road Suite 500
    West Palm Beach � FL � 33406
    Quantum Cyber N.V.05/18/2026200000730699.41

    144: Remarks and Signature

    Remarks
    Date of Notice
    05/22/2026

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Christian Nasser as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Guido Baechler

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $QUCY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $QUCY

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $QUCY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ben-Tzvi Avraham was granted 137,141 units of Ordinary Shares, increasing direct ownership by 6,857% to 139,141 units (SEC Form 4)

    4 - Quantum Cyber N.V. (0001874252) (Issuer)

    5/26/26 6:12:13 PM ET
    $QUCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider O'Rourke Peter claimed no ownership of stock in the company (SEC Form 3)

    3 - Quantum Cyber N.V. (0001874252) (Issuer)

    5/21/26 7:07:23 PM ET
    $QUCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Natan David was granted 137,141 units of Ordinary Shares (SEC Form 4)

    4 - Quantum Cyber N.V. (0001874252) (Issuer)

    5/21/26 7:07:00 PM ET
    $QUCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QUCY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Drones-as-a-Service Market Surges as AI, Automation, and Industrial Demand Drive Billion-Dollar Growth

    Market forecasts point to multi-billion-dollar expansion as businesses increasingly adopt outsourced drone operations to reduce costs and improve efficiencyNEW YORK, June 3, 2026 /CNW/ -- Market News Updates News Commentary - The concept of Drones as a Service (DaaS) is rapidly gaining momentum within the broader AI, automation, and industrial technology sectors. This trend is driven by businesses seeking cost-effective solutions for drone operations without the need to internally manage fleets. Instead of investing heavily in various aspects like hardware, software, pilots, compliance, and maintenance, companies are turning to subscription and on-demand service models to outsource their dro

    6/3/26 9:20:00 AM ET
    $ONDS
    $QUCY
    $UAVS
    Radio And Television Broadcasting And Communications Equipment
    Technology
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Quantum Cyber Publishes Inaugural Corporate Investor Presentation Showcasing System-of-Systems Autonomous Defense Platform, Eight Filed Patent Positions, LOIs With General Cherry and SOCOM, and $15 Million Debt-Free Balance Sheet

    WEST PALM BEACH, Florida, June 03, 2026 (GLOBE NEWSWIRE) -- Quantum Cyber N.V. (NASDAQ:QUCY) ("Quantum Cyber" or the "Company"), a Nasdaq-listed autonomous defense technology company assembling an AI-powered System-of-Systems platform for drone warfare, counter-UAS, and border security applications, today published its inaugural Corporate Investor Presentation. The full presentation is available at https://quantum-cyber.ai/investors/presentations. The 19-slide deck consolidates the Company's previously announced milestones, technology portfolio, and strategic positioning into a single investor-facing document. Key sections include: Battle-Validated Autonomy and the QC-Core Platform. Ukra

    6/3/26 8:13:00 AM ET
    $QUCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Quantum Cyber Assumes Direct Manufacturing of Autonomous Drone; Expands BP United Agreement

    WEST PALM BEACH, Florida, June 02, 2026 (GLOBE NEWSWIRE) -- Quantum Cyber N.V. (NASDAQ:QUCY) ("Quantum Cyber" or the "Company"), a Nasdaq-listed autonomous defense technology company assembling an AI-powered System-of-Systems platform for drone warfare, counter-UAS, and border security applications, today announced an expansion of its existing relationship with BP United Inc. ("BP United"), the developer of autonomous unmanned vehicle systems that form the foundation of the Company's autonomous drone platform. Quantum Cyber Assumes Direct Manufacturing ControlThe Company and BP United have executed a First Amendment to the Intellectual Property License Agreement dated May 12, 2026 (the "A

    6/2/26 7:30:00 AM ET
    $QUCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QUCY
    SEC Filings

    View All

    Mainz Biomed N.V. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Quantum Cyber N.V. (0001874252) (Filer)

    6/3/26 8:44:08 AM ET
    $QUCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Mainz Biomed N.V.

    DEF 14A - Quantum Cyber N.V. (0001874252) (Filer)

    6/1/26 5:19:22 PM ET
    $QUCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mainz Biomed N.V. filed SEC Form 8-K: Other Events

    8-K - Quantum Cyber N.V. (0001874252) (Filer)

    5/28/26 4:05:36 PM ET
    $QUCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QUCY
    Leadership Updates

    Live Leadership Updates

    View All

    Former Trump Administration VA Secretary Peter O'Rourke Sr. Joins Quantum Cyber's Board of Directors

    WEST PALM BEACH, Fla, May 14, 2026 (GLOBE NEWSWIRE) -- Quantum Cyber N.V. (NASDAQ:QUCY) ("Quantum Cyber" or the "Company"), a company assembling an AI-powered System-of-Systems autonomous defense platform spanning drone warfare, counter-UAS, demining, and command-and-control applications, today announced the appointment of Peter M. O'Rourke Sr. as an independent member of its Board of Directors, effective immediately. Mr. O'Rourke served as Acting Secretary of the U.S. Department of Veterans Affairs (VA) under the Trump administration in 2018, where he led over 380,000 employees and helped oversee one of the largest federal healthcare and benefits systems in the country, with an annual bu

    5/14/26 8:01:00 AM ET
    $NVAC
    $PFSA
    $QUCY
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $QUCY
    Financials

    Live finance-specific insights

    View All

    Quantum Cyber Publishes Inaugural Corporate Investor Presentation Showcasing System-of-Systems Autonomous Defense Platform, Eight Filed Patent Positions, LOIs With General Cherry and SOCOM, and $15 Million Debt-Free Balance Sheet

    WEST PALM BEACH, Florida, June 03, 2026 (GLOBE NEWSWIRE) -- Quantum Cyber N.V. (NASDAQ:QUCY) ("Quantum Cyber" or the "Company"), a Nasdaq-listed autonomous defense technology company assembling an AI-powered System-of-Systems platform for drone warfare, counter-UAS, and border security applications, today published its inaugural Corporate Investor Presentation. The full presentation is available at https://quantum-cyber.ai/investors/presentations. The 19-slide deck consolidates the Company's previously announced milestones, technology portfolio, and strategic positioning into a single investor-facing document. Key sections include: Battle-Validated Autonomy and the QC-Core Platform. Ukra

    6/3/26 8:13:00 AM ET
    $QUCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Quantum Cyber Assumes Direct Manufacturing of Autonomous Drone; Expands BP United Agreement

    WEST PALM BEACH, Florida, June 02, 2026 (GLOBE NEWSWIRE) -- Quantum Cyber N.V. (NASDAQ:QUCY) ("Quantum Cyber" or the "Company"), a Nasdaq-listed autonomous defense technology company assembling an AI-powered System-of-Systems platform for drone warfare, counter-UAS, and border security applications, today announced an expansion of its existing relationship with BP United Inc. ("BP United"), the developer of autonomous unmanned vehicle systems that form the foundation of the Company's autonomous drone platform. Quantum Cyber Assumes Direct Manufacturing ControlThe Company and BP United have executed a First Amendment to the Intellectual Property License Agreement dated May 12, 2026 (the "A

    6/2/26 7:30:00 AM ET
    $QUCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Quantum Cyber Announces Plans to Establish U.S.-Based Defense-Technology Manufacturing Complex to Support Drone and Autonomous Systems Delivery

    WEST PALM BEACH, Florida, May 28, 2026 (GLOBE NEWSWIRE) -- Quantum Cyber N.V. (NASDAQ:QUCY), a Nasdaq-listed autonomous defense technology company, today announced a strategic initiative to establish a U.S.-based defense-technology manufacturing complex intended to support the production and delivery of autonomous drone and defense systems to end customers across federal government, Homeland Security, local government, and commercial sectors. Illustrations shown are conceptual and provided for marketing and visualization purposes only. Certain depicted systems, capabilities, payloads, specifications, and operational use cases may be under development, subject to change, or not currently

    5/28/26 7:00:00 AM ET
    $QUCY
    Biotechnology: Pharmaceutical Preparations
    Health Care